<DOC>
	<DOCNO>NCT00090129</DOCNO>
	<brief_summary>The double-blind , placebo-controlled , randomize , multicenter study consist first treatment ( FT ) period follow either observation ( OB ) period re-treatment ( RT ) period open-label ( OL ) treatment period , depend FT period response , 4-week safety follow-up ( FU ) period . The purpose study evaluate safety efficacy onercept , administer 150 milligram ( mg ) three time week , compare match placebo , induction remission subject moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Onercept Treatment Re-Treatment Subjects With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Written inform consent , give prior studyrelated procedure part subject 's normal medical care , understand consent may withdraw subject time without prejudice future medical care At least 18 year age Female subject must neither pregnant breastfeeding , must lack childbearing potential , define either : Being postmenopausal ( least 12 month pass last menses ) surgically sterile , Using effective form contraception ( , condom , oral contraceptive intrauterine device ) ( Confirmation subject pregnant must establish negative urinary human chorionic gonadotrophin test within 7 day Study Day 1 . A pregnancy test require subject postmenopausal surgically sterile ) An outpatient status time enrollment Plaque psoriasis least 12 month Plaque psoriasis cover least 10 percent total body surface area PASI score 12.0 Candidate phototherapy systemic therapy Static Physician 's Global Assessment ( sPGA ) 3 Use one Nonsteroidal antiinflammatory drug ( NSAID ) treat psoriatic arthritis change chronic NSAID regimen 28 day Study Day 1 treat psoriatic arthritis Previous systemic treatment biologics , include interferon , and/or cytokines/anti cytokine ( example , anti tumor necrosis factoralpha , anticluster differentiation [ CD ] 4 , interleukin [ IL ] 10 , IL1ra , antiCD11a , etc . ) within 3 month Study Day 1 Participation investigational study experimental therapeutic procedure consider interfere study within 3 month Study Day 1 Treatment systemic corticosteroid intraarticular corticosteroid injection 28 day Study Day 1 Experimental offlabel treatment psoriasis and/or psoriatic arthritis azathioprine , hydroxyurea / hydroxycarbamide , mycophenolate , chlorambucil , leflunomide cyclophosphamide within 1 year prior Study Day 1 Treatment cyclosporin , methotrexate , oral retinoids ( , acitretin ) , fumaric acid ester within 28 day ( 3 month acitretin ) Study Day 1 Treatment topical therapy , Vitamin D derivative , corticosteroid , tar tar oil , dithranol chronic short contact therapy , salicylic acid topical retinoids , within 14 day Study Day 1 Phototherapy within 28 day Study Day 1 Use tan booth within 14 day Study Day 1 Abnormal liver function , define total bilirubin great equal 1.2 time upper limit normal value , ( except case Gilbert 's syndrome ) , aspartate aminotransferase , alanine aminotransferase alkaline phosphatase level great equal 2.5 time upper limit normal value Inadequate bone marrow reserve , define : Leukocytes less equal 3.5 * 10^9 per liter ( /L ) , Thrombocytes less equal 100 * 10^9 /L , Hemoglobin le equal 5 millimole per liter ( mmol/L ) ( 8.9 gram per deciliter ) . Abnormal renal function , define serum creatinine great 150 micromole per liter . Seropositivity human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ( HBsAg ) , Hepatitis C virus ( HCV ) Planned major surgery within treatment period study . History cancer precede 5 year ( except adequately treat basal cell carcinoma skin squamous cell carcinoma situ skin ) . Any history hematopoietic cancer History active tuberculosis , current active tuberculosis candidacy prophylactic therapy tuberculosis Active severe infection ( nonsevere infection discretion Investigator ) . History opportunistic infection ( example , viral , fungal , protozoal , bacterial ) 6 month precede Study Day 1 related clinical condition immunodeficiency Clinically significant serious abnormality electrocardiography chest Xray , ( discretion Investigator ) Other serious concomitant disorder incompatible study . In particular , subject congestive heart failure , prior current history blood dyscrasia central nervous system demyelinate disorder include study History current drug ( include narcotic ) abuse , current active problem alcohol abuse Requirement immunization , allergy desensitization vaccination entire study period ( recommended procedure schedule least 14 day prior Study Day 1 great 3 month last injection study drug ) , exception kill influenza vaccine allow time study Guttate , erythrodermic pustular psoriasis sole predominant form psoriasis . Evidence skin condition psoriasis ( example , eczema ) would interfere psoriasis disease assessment Clinically significant psoriasis flare screen time enrollment necessitate immediate relief ( Investigator 's discretion ) Live kill virus bacteria vaccine ( within 14 day Study Day 1 ) exception kill influenza vaccine allow prior Study Day 1 time study Bedridden status Previous use onercept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Moderate plaque psoriasis</keyword>
	<keyword>severe plaque psoriasis</keyword>
	<keyword>Onercept</keyword>
	<keyword>Placebo</keyword>
</DOC>